U C Bang1, L Hyldstrup, J E B Jensen. 1. Department of Endocrinology, University Hospital of Hvidovre, Kettegård Allé 30, 2650, Hvidovre, Denmark, ulrichbangbang@gmail.com.
Abstract
UNLABELLED: We used Danish registers to identify patients with osteoporosis, who had been treated with parathyroid hormone and evaluated the probability of developing cancer. We did not find an increased risk of cancer among the patients treated with parathyroid hormone. INTRODUCTION: We evaluated the incidences of malignancies and mortality in osteoporotic patients treated with rPTH. METHODS: Using Danish nationwide registers, we identified patients diagnosed with osteoporosis in the period 1995 through 2010. Each patient treated with rPTH ("case") was compared with 10 gender- and age-matched patients who did also have osteoporosis but did not receive rPTH ("control"). RESULTS: A total of 4,104 cases (80.3 % females) were identified. The mean age at the beginning of rPTH treatment was 70.9 (SD 9.7) years. During a follow-up time of 10,118 person-years for the cases and 88,005 person-years for the controls, a total of 255 cases (6.2 %) compared with 2,103 controls (5.1 %) experienced a cancer (Chi square, p = 0.003). We found an adjusted cancer related HR of 1.1 (95 %CI 0.9-1.4) among the cases. Lung cancer was the only cancer type with a significantly increased rate among patients receiving rPTH (HR 1.7; 95 % CI 1.3-2.3). No cases developed osteosarcomas and nine controls developed osteosarcoma. During follow-up, 627 (15.3 %) cases died and 4,175 (10.2 %) controls died, which yielded an excess mortality risk of 26 % (95 % CI 16-37 %). This could be due to differences in the prevalence of vertebral fractures between the rPTH-treated and non-treated patients. CONCLUSION: This study did not support the hypothesis describing a possible link between rPTH treatment and the development of cancer. We also conclude that osteosarcoma has not been diagnosed in any Danish patient receiving rPTH since the year 2003 when it was introduced on the market.
UNLABELLED: We used Danish registers to identify patients with osteoporosis, who had been treated with parathyroid hormone and evaluated the probability of developing cancer. We did not find an increased risk of cancer among the patients treated with parathyroid hormone. INTRODUCTION: We evaluated the incidences of malignancies and mortality in osteoporoticpatients treated with rPTH. METHODS: Using Danish nationwide registers, we identified patients diagnosed with osteoporosis in the period 1995 through 2010. Each patient treated with rPTH ("case") was compared with 10 gender- and age-matched patients who did also have osteoporosis but did not receive rPTH ("control"). RESULTS: A total of 4,104 cases (80.3 % females) were identified. The mean age at the beginning of rPTH treatment was 70.9 (SD 9.7) years. During a follow-up time of 10,118 person-years for the cases and 88,005 person-years for the controls, a total of 255 cases (6.2 %) compared with 2,103 controls (5.1 %) experienced a cancer (Chi square, p = 0.003). We found an adjusted cancer related HR of 1.1 (95 %CI 0.9-1.4) among the cases. Lung cancer was the only cancer type with a significantly increased rate among patients receiving rPTH (HR 1.7; 95 % CI 1.3-2.3). No cases developed osteosarcomas and nine controls developed osteosarcoma. During follow-up, 627 (15.3 %) cases died and 4,175 (10.2 %) controls died, which yielded an excess mortality risk of 26 % (95 % CI 16-37 %). This could be due to differences in the prevalence of vertebral fractures between the rPTH-treated and non-treated patients. CONCLUSION: This study did not support the hypothesis describing a possible link between rPTH treatment and the development of cancer. We also conclude that osteosarcoma has not been diagnosed in any Danish patient receiving rPTH since the year 2003 when it was introduced on the market.
Authors: Veronika Fedirko; Elio Riboli; H Bas Bueno-de-Mesquita; Sabina Rinaldi; Tobias Pischon; Teresa Norat; Eugène H J M Jansen; Fränzel J B van Duijnhoven; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Pierre Engel; Rudolf Kaaks; Birgit Teucher; Heiner Boeing; Brian Buijsse; Antonia Trichopoulou; Dimitrios Trichopoulos; Pagona Lagiou; Sabina Sieri; Paolo Vineis; Salvatore Panico; Domenico Palli; Rosario Tumino; Carla H van Gils; Petra H M Peeters; Maria-Dolores Chirlaque; Aurelio Barricarte Gurrea; Laudina Rodríguez; Esther Molina-Montes; Miren Dorronsoro; Catalina Bonet; Richard Palmqvist; Göran Hallmans; Timothy J Key; Konstantinos K Tsilidis; Kay-Tee Khaw; Isabelle Romieu; Kurt Straif; Petra A Wark; Dora Romaguera; Mazda Jenab Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-03-04 Impact factor: 4.254
Authors: J A Kanis; O Johnell; A Oden; H Johansson; C De Laet; J A Eisman; S Fujiwara; H Kroger; E V McCloskey; D Mellstrom; L J Melton; H Pols; J Reeve; A Silman; A Tenenhouse Journal: Osteoporos Int Date: 2004-06-03 Impact factor: 4.507
Authors: John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold Journal: Toxicol Pathol Date: 2002 May-Jun Impact factor: 1.902
Authors: Ashley R Sweeney-Ambros; Amy E Biggs; Nicholas D Zimmerman; Kenneth A Mann; Timothy A Damron; Megan E Oest Journal: J Orthop Res Date: 2022-03-10 Impact factor: 3.102
Authors: Christopher M Bartlow; Megan E Oest; Kenneth A Mann; Nicholas D Zimmerman; Bilal B Butt; Timothy A Damron Journal: J Orthop Res Date: 2016-10-03 Impact factor: 3.494
Authors: Bente L Langdahl; Östen Ljunggren; Claude-Laurent Benhamou; Fernando Marin; George Kapetanos; Tomaz Kocjan; Eric Lespessailles; Nicola Napoli; Tatjana Nikolic; Helmut Petto; Thomas Moll; Erik Lindh Journal: Calcif Tissue Int Date: 2016-04-30 Impact factor: 4.333